Opella Healthcare Files for IPO Following $16.9 Billion Sanofi Spin-off

At the end of September, foreign media reported that Sanofi received separate bids from PAI Partners and CD&R for Opella, with a valuation potentially reaching 15.5 billion euros (approximately 16.9 billion US dollars). Currently, Opella has 11,000 employees worldwide, 13 manufacturing bases, and four research and innovation centers. Sanofi currently plans to sell its remaining shares in the company in the coming years.

On October 21, 2024, both parties entered the exclusive negotiation phase. Additionally, during the spin-off process, Bpifrance, France's national investment bank, is expected to participate as a minority shareholder with an approximately 2% stake.



In the first half of 2024, Opella accounted for approximately 13.3% of Sanofi's total revenue, with a performance of 2.8 billion euros.

In 2023, Opella's sales reached 5.18 billion euros. Sanofi stated that Opella ranks third in the over-the-counter (OTC) medicines, vitamins, minerals, and supplements market. Well-known branded drugs include Allegra (fexofenadine hydrochloride) for allergies, pain reliever Doliprane, Novanight, Icy Hot, Dulcolax, and more.

Potential buyer, CD&R, a giant investment firm founded in 1978, manages over $30 billion in investments.

Previously, Johnson & Johnson spun off and listed its consumer business, establishing Kenvue.
GSK's consumer business was spun off and listed, forming Haleon.

Sanofi is a global leading innovative pharmaceuticals and healthcare company with the mission of "Chasing Scientific Miracles, Revitalizing the Radiance of Life." As one of the first multinational companies to enter China after the reform and opening-up, Sanofi established its office in China in 1982. Currently, it operates 12 multi-modal offices, 3 production bases, 4 major R&D centers, and 1 digital innovation hub, with diversified businesses covering pharmaceuticals, human vaccines, and consumer healthcare.

Sanofi achieved a breakthrough in China with 12 innovative products and indications approved in 2023, contributing €1.522 billion in sales performance in the first half of 2024.